Detailed usage and medication recommendations for Ixazomib (Enleri)

1. Drug introduction and mechanism of action

Ixazomib (Ixazomib) is an oral reversible proteasome inhibitor and a targeted anti-tumor small molecule drug. Its main mechanism of action is to inhibit the activity of 26S proteasome so that abnormal proteins in tumor cells cannot be degraded, thereby inducing cell apoptosis. As an important part of the treatment plan for patients with multiple myeloma (MM), ixazomib is usually used in combination with lenalidomide (Lenalidomide) and dexamethasone (Dexamethasone) and is recommended by international guidelines for initial treatment, relapsed or refractory multiple myeloma.

Clinical studies have shown that the ixazomib combination regimen can significantly prolong progression-free survival (PFS) and overall response rate (ORR). Compared with intravenous proteasome inhibitors such as bortezomib, ixazomib is an oral administration method, which is more convenient to use and has higher patient compliance. Its main adverse reactions include hematological toxicity (neutropenia, thrombocytopenia), gastrointestinal reactions (nausea, diarrhea), fatigue, peripheral neuropathy and infection risk, but the overall tolerance is good.

2. Standard usage, dosage and dosage regimen

The recommended dose of ixazomib is 4 mg orally once a week for 28 days. A standard dosing regimen usually is as follows:

1.Combination therapy: When used in combination with lenalidomide and dexamethasone, ixazomib is taken orally daily4 mg, once a week (such as the 1st, 8th, 15th day), and every 28th day is a course of treatment. Take lenalidomide and dexamethasone at the same time according to the dosage directed by your doctor.

2.Single drug use: For patients who have poor tolerance to the combination regimen or are relapsed and refractory, oral single drug may be considered, and still administered at a rate of 4 mg per week and every 28 days.

3.Dose adjustment: For patients with moderate renal impairment (CrCl 30–59 mL/min), there is usually no need to adjust; patients with severe renal impairment or dialysis need to reduce the dose as appropriate under the guidance of a doctor. Patients with mild to moderate hepatic dysfunction can use it at regular doses. Patients with severe hepatic impairment should be cautious and consider lowering the dose.

The medicine should be taken at a fixed time every day, on an empty stomach or with food. Avoid taking it with grapefruit juice to avoid affecting drug metabolism.

3. Treatment Arrangement and Monitoring Suggestions

The course of ixazomib treatment should be flexibly adjusted according to the patient's condition, efficacy and tolerance. It is generally recommended to continue treatment until disease progression or unacceptable toxicity occurs. After each course of treatment, the efficacy needs to be evaluated through blood routine, blood biochemistry and bone marrow, and blood pressure, nervous system and renal function should be monitored.

In the early stage of treatment (the first 1–2 courses), focus on monitoring platelet, neutrophil and serum protein levels to prevent the risk of infection and bleeding. At the same time, attention should be paid to gastrointestinal reactions, such as nausea, diarrhea, constipation, etc., and discomfort should be alleviated through reasonable diet, drug intervention, or adjusting the administration time. Although the incidence of peripheral neuropathy is low, patients who take long-term medication still need to regularly evaluate numbness or pain in their hands and feet and adjust the dosage in a timely manner.

During home medication, patients should maintain adequate fluid intake to avoid dehydration, and regularly record medication time and adverse reactions to provide doctors with a basis for adjustment. In addition, patients are advised to review blood pressure, electrocardiogram, and liver and kidney function before and after each course of treatment in order to detect potential risks early.

4. Special groups and medication precautions

1. Patients with renal insufficiency: No dose adjustment is required for mild to moderate cases; dose reduction and close monitoring of blood indicators are required for severe cases.

2. Patients with hepatic insufficiency: Mild to moderate patients can use the conventional dose; patients with severe hepatic impairment should be cautious and adjust the dose or extend the treatment interval if necessary.

3.Combined medication: Ixazomib is metabolized by CYP3A and strongly CYP3AThe combined use of inhibitors (such as ketoconazole, clarithromycin) may increase blood concentration, and the dose should be reduced as appropriate; combined use with CYP3A inducers may reduce the efficacy, and should be avoided or the dose adjusted.

4.Pregnant women and lactating women: There is insufficient safety data and should be avoided. Women of childbearing age need to take effective contraceptive measures.

5.Children and elderly patients: There is a lack of sufficient clinical research and individualized assessment of risks and doses is required.

5. Efficacy evaluation and long-term management

The ixazomib combination regimen has shown the advantages of higher response rate and prolonged progression-free survival in patients with multiple myeloma. Efficacy evaluation is usually achieved through serum MMprotein, bone marrow cytology examination and imaging evaluation. If the patient has poor efficacy after multiple consecutive courses of treatment, dosage adjustment, combination with other targeted drugs, or switching regimens may be considered.

During long-term medication, blood routine and liver and kidney functions should be continuously monitored, while attention should be paid to the management of adverse reactions. Through standardized medication guidance, periodic evaluation and patient self-management, ixazomib can achieve the best clinical efficacy while ensuring safety.

Reference materials:https://www.drugs.com/